title: Management of Vaginal Cancer.
abstract: BACKGROUND
  Vaginal cancer is a rare gynecologic cancer with very little documentation.
  
  
  OBJECTIVE
  Literature search to have useful information for the management of vaginal cancer and share.
  
  
  METHODS
  We have searched the PUBMED database, Google search engine and other database. A total of 26 references were taken into account.
  
  
  CONCLUSIONS
  Once spread from primary other cancers or vulva is ruled out, vaginal cancer is designated to be primary in origin. It was revealed that majority of vaginal cancers reported are squamous cell carcinomas. The most common risk factors implicated are Human Papiloma Virus, age. Most common presenting symptoms were abnormal vaginal bleeding,. Diagnosis requires pathological confirmation. Management depends on staging work-up. Vaginal cancer is staged by FIGO system of staging and TNM staging. There are many prognostic factors influencing the choice of treatment. Lymph node metastasis is one of the important prognostic factors, others to mention are histology, size, age. In a recent SEER analysis of over 2000 patients, the 5 year disease specific survival was 84% for stage 1, 75% for stage II and 57% for advanced tumors. Early carcinomas are generally treated with either surgery or radiation therapy. Advanced cancers are treated with radiation therapy with simultaneous administration of combined chemotherapy. Preventive strategies include safe sex and HPV vaccination.
  
  
  CONCLUSIONS
  Primary vaginal cancer is a rare entity, if there is no history of cancer cervix or vulva in past or absence of cervical squamous cell carcinoma or vulvar carcinoma within 5 years is usually considered as primary vaginal cancer. Though early stage vaginal cancers have better outcome treated with surgery or radiotherapy or surgery followed by radiotherapy, radiotherapy alone is preferred mode of treatment in vaginal cancers.
authors.forename: S B L
authors.initials: SB
authors.lastname: Shrivastava
authors.forename: Gaurav
authors.initials: G
authors.lastname: Agrawal
authors.forename: Megha
authors.initials: M
authors.lastname: Mittal
authors.affiliation: BIMR Oncology Centre, BIMR Hospitals, Gwalior (M.P.), India.
authors.forename: Priyanshi
authors.initials: P
authors.lastname: Mishra
mesh_terms: D000328:Adult; D001707:Biopsy, Needle; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000150:complications / Q000473:pathology*; D011379:Prognosis; D035583:Rare Diseases; D018570:Risk Assessment; D018426:SEER Program; D016896:Treatment Outcome; D014625:Vaginal Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy / Q000821:virology*